Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 76, Issue 2, Pages 233-247
Publisher
Wiley
Online
2013-05-23
DOI
10.1111/bcp.12164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
- (2013) David Eastwood et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial
- (2012) Ignacio Melero et al. CANCER RESEARCH
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospects for TIM3-Targeted Antitumor Immunotherapy
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- 4-1BB signaling beyond T cells
- (2011) Dass S Vinay et al. Cellular & Molecular Immunology
- Science gone translational: the OX40 agonist story
- (2011) Andrew D. Weinberg et al. IMMUNOLOGICAL REVIEWS
- CD27-deficient mice show normal NK-cell differentiation but impaired function upon stimulation
- (2011) Veerle De Colvenaer et al. IMMUNOLOGY AND CELL BIOLOGY
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
- (2011) Taku Okazaki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
- (2011) Grazia Graziani et al. PHARMACOLOGICAL RESEARCH
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- Emerging Tim-3 functions in antimicrobial and tumor immunity
- (2011) Kaori Sakuishi et al. TRENDS IN IMMUNOLOGY
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- The CD4-like molecule LAG-3, biology and therapeutic applications
- (2010) Sophie Sierro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
- (2010) Laurent Derré et al. JOURNAL OF CLINICAL INVESTIGATION
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 is required for regulatory T cell–mediated control of colitis
- (2010) Thibault Griseri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- (2010) Kaan Harmankaya et al. MEDICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
- (2010) Antoni Ribas SEMINARS IN ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- CD4+regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
- (2009) Randall H. Friedline et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Editorial: Therapeutic potential of targeting BTLA
- (2009) Alison Crawford et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator
- (2008) Yoshihiro Oya et al. ARTHRITIS AND RHEUMATISM
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies
- (2008) Juliet C. Gray et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started